Common Mental Disorders — MCQs
On this page
A 28-year-old woman presents with recurrent panic attacks over 4 months. She describes attacks occurring both in crowded places and at home alone, sometimes waking her from sleep. During attacks she experiences palpitations, breathlessness, chest tightness, dizziness, and fear of dying. She has developed extensive avoidance of public transport and shopping centres. Cardiac investigations including ECG and echocardiogram are normal. What is the most appropriate initial psychological intervention?
A 57-year-old woman with a 10-week history of severe depression has been taking venlafaxine 225mg daily for 8 weeks with minimal improvement. She has previously failed adequate trials of sertraline and mirtazapine. She has no psychotic symptoms but has persistent suicidal ideation without specific plans. Her medical history includes well-controlled hypertension. What is the most appropriate next step in her management?
A 49-year-old man presents with an 8-week history of low mood, fatigue, poor appetite, and disturbed sleep. He describes waking at 4am unable to return to sleep, feeling worst in the early morning with slight improvement as the day progresses. He has lost interest in his hobbies and feels slowed down. There is no diurnal variation in his physical symptoms. His PHQ-9 score is 19. Which feature of his presentation most specifically indicates melancholic features according to diagnostic classifications?
A 36-year-old woman with panic disorder has been taking sertraline 50mg daily for 3 weeks. She reports some reduction in anticipatory anxiety but continues to experience 3-4 panic attacks weekly. She is tolerating the medication well with only mild nausea initially. She asks how long it typically takes for panic attacks to improve with SSRI treatment. What is the most appropriate response regarding the expected timeline for therapeutic response in panic disorder?
A 41-year-old accountant presents with a 6-month history of excessive worry about work performance, family health, and finances. She reports constant muscle tension, difficulty concentrating, irritability, and poor sleep. She avoids social situations due to worry about being judged. Her GAD-7 score is 16. Which feature most clearly distinguishes generalised anxiety disorder from social anxiety disorder in this presentation?
A 54-year-old woman presents with a 7-week history of low mood, anhedonia, poor concentration, and insomnia. She has lost 5kg in weight and feels she is a burden to her family. She has no past psychiatric history. Her PHQ-9 score is 22. Physical examination and routine blood tests are normal. According to ICD-10 criteria, what is the minimum number of total symptoms (core and additional) required to diagnose a severe depressive episode?
A 44-year-old solicitor presents with a 9-week history of low mood, anhedonia, fatigue, and reduced concentration affecting his work performance. He has no previous psychiatric history. On systematic enquiry, he reports drinking 6-8 units of alcohol daily for the past 3 months to help him sleep. Liver function tests show GGT 185 U/L (normal <50), with other results normal. What is the most appropriate initial approach to management?
A 52-year-old man with panic disorder presents to his GP reporting that for the past 3 months, he has been having panic attacks exclusively upon waking from sleep, typically 2-3 hours after falling asleep. He has no daytime attacks. He is otherwise healthy with no sleep apnea or other medical conditions. His nocturnal panic attacks have identical symptoms to his previous daytime attacks. What aspect of nocturnal panic attacks is most important for the GP to understand when counseling this patient?
A 36-year-old woman with moderate depression has been taking citalopram 20mg daily for 5 weeks. She reports some improvement in energy levels and sleep, but low mood and anhedonia persist. She asks whether she should increase the dose or try a different medication. What is the most appropriate response based on evidence-based guidelines?
A 48-year-old woman with severe depression and prominent psychomotor retardation has been on optimal doses of fluoxetine for 8 weeks and subsequently venlafaxine for 10 weeks, with no significant improvement. Augmentation with lithium and then quetiapine has been tried without success. She has lost 8kg in weight and is drinking minimal fluids. Her psychiatrist recommends electroconvulsive therapy (ECT). What is the most likely clinical reason ECT is being considered at this stage?
Common Mental Disorders UK Medical PG Practice Questions and MCQs
Question 11: A 28-year-old woman presents with recurrent panic attacks over 4 months. She describes attacks occurring both in crowded places and at home alone, sometimes waking her from sleep. During attacks she experiences palpitations, breathlessness, chest tightness, dizziness, and fear of dying. She has developed extensive avoidance of public transport and shopping centres. Cardiac investigations including ECG and echocardiogram are normal. What is the most appropriate initial psychological intervention?
- A. Psychodynamic psychotherapy focusing on unconscious conflicts underlying the anxiety
- B. Applied relaxation training to reduce physiological arousal during panic attacks
- C. Cognitive behavioural therapy including exposure to feared situations and cognitive restructuring of catastrophic misinterpretations (Correct Answer)
- D. Mindfulness-based stress reduction to increase acceptance of panic sensations
- E. Eye movement desensitisation and reprocessing (EMDR) to process traumatic memories
Explanation: ***Cognitive behavioural therapy including exposure to feared situations and cognitive restructuring of catastrophic misinterpretations***- **Cognitive Behavioural Therapy (CBT)** is the **first-line evidence-based psychological intervention** for **Panic Disorder** with **agoraphobia**, effectively breaking the cycle of **catastrophic misinterpretations** of bodily sensations. - Its key components, such as **interoceptive exposure** (to physiological symptoms) and **in vivo exposure** (to feared situations), directly target the **panic attacks** and the **agoraphobic avoidance** presented by the patient.*Psychodynamic psychotherapy focusing on unconscious conflicts underlying the anxiety*- This approach has **less direct evidence** for the initial, acute management of **panic disorder** compared to CBT.- It primarily explores **unconscious conflicts** and **early life experiences**, which are not the immediate targets for effective symptom reduction in panic disorder.*Applied relaxation training to reduce physiological arousal during panic attacks*- While beneficial for **reducing physiological arousal**, it is **less comprehensive** than CBT for panic disorder.- It does not directly address the **cognitive misinterpretations** of bodily sensations or the specific **agoraphobic avoidance behaviors** that are central to this patient's presentation.*Mindfulness-based stress reduction to increase acceptance of panic sensations*- **Mindfulness-based stress reduction** can be a useful **adjunct** for managing general anxiety and increasing distress tolerance but is **not the primary initial intervention** for panic disorder with significant agoraphobia.- It focuses more on **acceptance** rather than the active **exposure** and **cognitive restructuring** necessary to overcome panic attacks and avoidance.*Eye movement desensitisation and reprocessing (EMDR) to process traumatic memories*- **EMDR** is an evidence-based treatment specifically for **Post-Traumatic Stress Disorder (PTSD)**.- There is **no indication of a traumatic memory** as the underlying cause of the panic attacks in the patient's history, making it an inappropriate initial intervention.
Question 12: A 57-year-old woman with a 10-week history of severe depression has been taking venlafaxine 225mg daily for 8 weeks with minimal improvement. She has previously failed adequate trials of sertraline and mirtazapine. She has no psychotic symptoms but has persistent suicidal ideation without specific plans. Her medical history includes well-controlled hypertension. What is the most appropriate next step in her management?
- A. Augment venlafaxine with lithium and continue for a further 4-6 weeks (Correct Answer)
- B. Switch to a monoamine oxidase inhibitor after appropriate washout period
- C. Refer for urgent psychiatric assessment for consideration of electroconvulsive therapy
- D. Add an atypical antipsychotic such as quetiapine for augmentation
- E. Switch to duloxetine as an alternative SNRI with a different side effect profile
Explanation: ***Augment venlafaxine with lithium and continue for a further 4-6 weeks*** - This patient has **treatment-resistant depression (TRD)**, defined as failure to respond to two or more antidepressants of different classes at adequate doses. - **Lithium augmentation** has the strongest evidence base for efficacy in TRD, significantly increasing response rates when added to an existing antidepressant like **venlafaxine**. *Switch to a monoamine oxidase inhibitor after appropriate washout period* - **MAOIs** are generally reserved as a later-line treatment due to their complex **dietary restrictions** and risk of hypertensive crisis. - Switching would require a lengthy **washout period** (2 weeks or more), during which the patient's depressive symptoms and suicidal ideation could worsen without treatment. *Refer for urgent psychiatric assessment for consideration of electroconvulsive therapy* - **Electroconvulsive therapy (ECT)** is highly effective but usually indicated for **life-threatening** depression, such as severe catatonia or immediate high risk of suicide. - While the patient has suicidal ideation, she lacks **psychotic symptoms** or a specific plan, making a trial of pharmacological augmentation appropriate first. *Add an atypical antipsychotic such as quetiapine for augmentation* - While **atypical antipsychotics** are used for augmentation, lithium currently holds a superior evidence profile for non-psychotic **treatment-resistant depression**. - Antipsychotics carry a significant metabolic side effect burden, including **weight gain** and potential **glucose intolerance**, which may be less desirable than lithium in this clinical context. *Switch to duloxetine as an alternative SNRI with a different side effect profile* - **Duloxetine** belongs to the same class (**SNRI**) as venlafaxine; switching within the same class after a failure is generally less effective than augmentation. - Effective management of TRD prioritizes switching to a **different drug class** or adding an augmenting agent rather than a lateral switch.
Question 13: A 49-year-old man presents with an 8-week history of low mood, fatigue, poor appetite, and disturbed sleep. He describes waking at 4am unable to return to sleep, feeling worst in the early morning with slight improvement as the day progresses. He has lost interest in his hobbies and feels slowed down. There is no diurnal variation in his physical symptoms. His PHQ-9 score is 19. Which feature of his presentation most specifically indicates melancholic features according to diagnostic classifications?
- A. The 8-week duration of symptoms meeting criteria for a depressive episode
- B. The combination of early morning wakening with diurnal mood variation showing worst symptoms in the morning (Correct Answer)
- C. The presence of psychomotor retardation with subjective feeling of being slowed down
- D. Loss of interest in previously enjoyed activities indicating anhedonia
- E. The PHQ-9 score of 19 indicating moderately severe depression
Explanation: ***The combination of early morning wakening with diurnal mood variation showing worst symptoms in the morning*** - **Early morning awakening** (terminal insomnia, usually at least 2 hours before habitual time) and **diurnal variation** of mood (mood worst in the morning) are classic vegetative symptoms specific to **melancholic depression** (DSM-5 specifier "with melancholic features"). - These features reflect a distinct neurobiological pattern, often associated with a better response to biological treatments like **antidepressants** or **ECT**, differentiating it from atypical depression. *The 8-week duration of symptoms meeting criteria for a depressive episode* - The **duration** of symptoms (minimum 2 weeks) is a general criterion for **Major Depressive Disorder**, not specific to melancholic features. - It indicates the presence of a depressive episode but does not differentiate between subtypes like melancholic, atypical, or anxious depression. *The presence of psychomotor retardation with subjective feeling of being slowed down* - While **psychomotor retardation** (observable slowing of thought and movement) is a common feature of severe depression, it can also be present in other severe depressive episodes without specific melancholic features. - It is less specific than the **diurnal variation** and **early morning awakening** for defining melancholic specifiers according to diagnostic criteria. *Loss of interest in previously enjoyed activities indicating anhedonia* - **Anhedonia** (loss of interest or pleasure) is a **core diagnostic criterion** for *any* major depressive episode, not just melancholic. At least one of depressed mood or anhedonia is required for diagnosis. - While often severe in melancholic depression, its presence alone does not specifically indicate melancholic features according to diagnostic classifications. *The PHQ-9 score of 19 indicating moderately severe depression* - A **PHQ-9 score** of 19 indicates **moderately severe depression**, reflecting the overall symptom burden. - However, the PHQ-9 is a **severity scale** and a **screening tool**, not a diagnostic instrument for differentiating specific depressive subtypes like **melancholic features**.
Question 14: A 36-year-old woman with panic disorder has been taking sertraline 50mg daily for 3 weeks. She reports some reduction in anticipatory anxiety but continues to experience 3-4 panic attacks weekly. She is tolerating the medication well with only mild nausea initially. She asks how long it typically takes for panic attacks to improve with SSRI treatment. What is the most appropriate response regarding the expected timeline for therapeutic response in panic disorder?
- A. Maximum benefit is usually achieved within 2-4 weeks of starting treatment
- B. Panic attacks should resolve within 1 week if the medication is going to be effective
- C. Full therapeutic effect on panic attacks typically takes 8-12 weeks, with gradual improvement from 4-6 weeks (Correct Answer)
- D. Response should be evident within 6 weeks; if not, the medication is unlikely to be effective
- E. Improvement in panic attacks parallels improvement in general anxiety, typically within 2-3 weeks
Explanation: ***Full therapeutic effect on panic attacks typically takes 8-12 weeks, with gradual improvement from 4-6 weeks*** - In **panic disorder**, the full therapeutic response to **SSRIs** is often slower than for other anxiety symptoms, typically requiring **8-12 weeks** for substantial reduction or cessation of panic attacks. - The patient has only been on **sertraline** for 3 weeks, which is an insufficient duration to assess the medication's full impact on **panic attack frequency**. *Maximum benefit is usually achieved within 2-4 weeks of starting treatment* - While side effects often subside by this time, and some initial relief from **generalized anxiety** may occur, maximal **antipanic effects** are rarely observed within the first month. - This timeframe is typically too short for the significant **neuroadaptive changes** required to fully mitigate panic attacks. *Panic attacks should resolve within 1 week if the medication is going to be effective* - **SSRIs** have a **delayed onset of action**, requiring several weeks for **neuroreceptor downregulation** and downstream signaling changes to achieve therapeutic effects. - Expecting resolution of **panic attacks** within 1 week is clinically unrealistic and may lead to premature conclusions about **treatment ineffectiveness**. *Response should be evident within 6 weeks; if not, the medication is unlikely to be effective* - While some improvement in **panic symptoms** may be observed by 6 weeks, this is not the definitive timeframe for determining **treatment failure** in panic disorder. - Many patients require **dose optimization** and a full course of at least 8-12 weeks before evaluating the efficacy of the **pharmacotherapy**. *Improvement in panic attacks parallels improvement in general anxiety, typically within 2-3 weeks* - **Anticipatory anxiety** (the patient's 'anticipatory anxiety reduction') often improves earlier than the actual **paroxysmal panic attacks**. - The **neurobiological pathways** involved in acute panic are distinct and generally take longer to stabilize under **serotonergic modulation** compared to generalized anxiety.
Question 15: A 41-year-old accountant presents with a 6-month history of excessive worry about work performance, family health, and finances. She reports constant muscle tension, difficulty concentrating, irritability, and poor sleep. She avoids social situations due to worry about being judged. Her GAD-7 score is 16. Which feature most clearly distinguishes generalised anxiety disorder from social anxiety disorder in this presentation?
- A. The presence of muscle tension and difficulty concentrating
- B. The 6-month duration of symptoms
- C. The excessive worry extending across multiple domains rather than being limited to social evaluation (Correct Answer)
- D. The GAD-7 score of 16 indicating moderate to severe anxiety
- E. The presence of sleep disturbance and irritability
Explanation: ***The excessive worry extending across multiple domains rather than being limited to social evaluation***- The hallmark of **Generalized Anxiety Disorder (GAD)** is pervasive, "free-floating" anxiety regarding various aspects of life, such as **work, health, and finances**, rather than a single specific trigger.- In contrast, **Social Anxiety Disorder** is strictly characterized by a fear of **scrutiny** or **negative evaluation** by others in social or performance-based situations.*The presence of muscle tension and difficulty concentrating*- These are **somatic and cognitive symptoms** commonly found in GAD but are not unique enough to rule out other anxiety disorders.- While they support a diagnosis of GAD, they do not help distinguish it from the specific focus on social evaluation seen in Social Anxiety Disorder.*The 6-month duration of symptoms*- A **6-month duration** is a core diagnostic criterion for GAD according to the **DSM-5**, but it is also common for Social Anxiety Disorder to be chronic.- Mentioning the timeline confirms the chronicity required for diagnosis but does not differentiate between the **themes of the worries**.*The GAD-7 score of 16 indicating moderate to severe anxiety*- The **GAD-7** is a screening tool used to measure the **severity** of anxiety symptoms rather than to provide a definitive differential diagnosis.- A high score indicates significant clinical impairment but does not specify whether the etiology is generalized or social in nature.*The presence of sleep disturbance and irritability*- These symptoms are part of the **diagnostic criteria** for GAD but are frequently associated with various other stress and mood disorders.- They represent the **physiological arousal** of anxiety but do not clarify the primary focus of the patient's apprehension or fear.
Question 16: A 54-year-old woman presents with a 7-week history of low mood, anhedonia, poor concentration, and insomnia. She has lost 5kg in weight and feels she is a burden to her family. She has no past psychiatric history. Her PHQ-9 score is 22. Physical examination and routine blood tests are normal. According to ICD-10 criteria, what is the minimum number of total symptoms (core and additional) required to diagnose a severe depressive episode?
- A. At least 6 symptoms including all 3 core symptoms
- B. At least 7 symptoms including all 3 core symptoms
- C. At least 8 symptoms including all 3 core symptoms (Correct Answer)
- D. At least 5 symptoms including at least 2 core symptoms
- E. At least 9 symptoms including all 3 core symptoms
Explanation: ***At least 8 symptoms including all 3 core symptoms*** - Under **ICD-10 criteria**, a **severe depressive episode** mandates the presence of all three **core symptoms**: depressed mood, anhedonia (loss of interest or pleasure), and decreased energy or increased fatigability. - In addition to these three core symptoms, a minimum of **five additional symptoms** from the standard list of depressive features must be present, totaling at least **eight symptoms** for diagnosis. *At least 6 symptoms including all 3 core symptoms* - This criterion typically describes a **moderate depressive episode** under **ICD-10**, which requires at least two core symptoms and a total of six or more symptoms, or all three core symptoms and three or more additional symptoms. - It does not meet the specified minimum symptom count for a **severe depressive episode**. *At least 7 symptoms including all 3 core symptoms* - While seven symptoms indicate significant distress and likely a **moderate to severe** presentation, **ICD-10** specifically requires a minimum of **eight symptoms** including all three core symptoms for a diagnosis of severe depression. - This threshold is often considered the higher end of a **moderate depressive episode** or just below the minimum for severe. *At least 5 symptoms including at least 2 core symptoms* - This symptom count aligns with the **ICD-10 criteria** for a **mild depressive episode**, which requires at least two core symptoms and a total of four to five symptoms. - It is insufficient for diagnosing a **severe depressive episode**, which demands a higher number and intensity of symptoms. *At least 9 symptoms including all 3 core symptoms* - Although a patient presenting with nine symptoms would unequivocally meet the criteria for a **severe depressive episode**, this option does not represent the **minimum number** required by **ICD-10**. - The established minimum for severe depression is **eight symptoms**, including all three core symptoms.
Question 17: A 44-year-old solicitor presents with a 9-week history of low mood, anhedonia, fatigue, and reduced concentration affecting his work performance. He has no previous psychiatric history. On systematic enquiry, he reports drinking 6-8 units of alcohol daily for the past 3 months to help him sleep. Liver function tests show GGT 185 U/L (normal <50), with other results normal. What is the most appropriate initial approach to management?
- A. Start sertraline 50mg daily immediately as he has moderate depression
- B. Advise alcohol reduction and reassess mood after 4 weeks of abstinence (Correct Answer)
- C. Refer to community alcohol services before addressing mood symptoms
- D. Start mirtazapine 30mg at night to address both depression and sleep
- E. Admit for inpatient alcohol detoxification before treating depression
Explanation: ***Advise alcohol reduction and reassess mood after 4 weeks of abstinence*** - Alcohol is a **central nervous system depressant** that can cause or exacerbate depressive symptoms; therefore, clarifying the primary diagnosis requires a period of **abstinence** (typically 3-4 weeks). - Clinical guidelines suggest that treating underlying **harmful alcohol use** (evidenced by the elevated **GGT**) often leads to spontaneous improvement in mood symptoms, avoiding unnecessary medication. *Start sertraline 50mg daily immediately as he has moderate depression* - Antidepressants are less effective when used concurrently with active **alcohol misuse**, as ethanol interferes with neurotransmitter regulation and recovery. - It is premature to diagnose a **primary depressive disorder** until the effects of a known depressant (alcohol) have been removed. *Refer to community alcohol services before addressing mood symptoms* - While referral may eventually be needed, the patient is currently engaging with **primary care**, and his intake (42-56 units/week) can often be initially managed with **brief interventions**. - This approach is too narrow, as it ignores the need to monitor and plan for the clinical reassessment of his **mental health** status. *Start mirtazapine 30mg at night to address both depression and sleep* - Using **mirtazapine** for its sedative properties may mask the sleep disturbance without addressing the **alcohol-induced** disruption of sleep architecture. - **Polypharmacy** involving sedating medications and daily alcohol significantly increases the risk of excessive **CNS depression** and respiratory suppression. *Admit for inpatient alcohol detoxification before treating depression* - Inpatient detoxification is generally reserved for patients with high levels of **physical dependence**, severe withdrawal risks, or failed community attempts, which are not indicated here. - The patient's consumption of 6-8 units daily is better managed through **gradual reduction** and community-based support rather than **acute hospitalization**.
Question 18: A 52-year-old man with panic disorder presents to his GP reporting that for the past 3 months, he has been having panic attacks exclusively upon waking from sleep, typically 2-3 hours after falling asleep. He has no daytime attacks. He is otherwise healthy with no sleep apnea or other medical conditions. His nocturnal panic attacks have identical symptoms to his previous daytime attacks. What aspect of nocturnal panic attacks is most important for the GP to understand when counseling this patient?
- A. Nocturnal panic attacks suggest an underlying cardiac arrhythmia and require cardiology referral
- B. Nocturnal panic attacks are a distinct condition requiring different treatment than daytime panic disorder
- C. Nocturnal panic attacks occur during non-REM sleep and are part of panic disorder requiring standard treatment (Correct Answer)
- D. Nocturnal panic attacks indicate comorbid sleep disorder and require sleep study
- E. Nocturnal panic attacks are always secondary to nightmares and require trauma-focused therapy
Explanation: ***Nocturnal panic attacks occur during non-REM sleep and are part of panic disorder requiring standard treatment***- **Nocturnal panic attacks** are a recognized part of the **Panic Disorder** spectrum, occurring in up to 45% of affected patients, and typically occur during the transition from **Stage 2 to Stage 3 (non-REM) sleep**.- Because they are physiologically consistent with daytime attacks, they respond to identical standard treatments, including **SSRIs** and **Cognitive Behavioral Therapy (CBT)**.*Nocturnal panic attacks suggest an underlying cardiac arrhythmia and require cardiology referral*- While symptoms like palpitations occur, these attacks are identical to the patient's previous **psychological panic attacks**, making a primary **cardiac arrhythmia** unlikely in an otherwise healthy patient.- A referral is not routinely indicated unless there are specific clinical red flags for **structural heart disease** or specific EKG abnormalities.*Nocturnal panic attacks are a distinct condition requiring different treatment than daytime panic disorder*- Clinical evidence suggests that individuals with nocturnal attacks have similar **comorbidity profiles** and treatment responses as those with only daytime symptoms.- They are categorized under the same **DSM-5 criteria** for Panic Disorder and do not necessitate a specialized pharmacological protocol.*Nocturnal panic attacks indicate comorbid sleep disorder and require sleep study*- **Polysomnography** is generally reserved for patients showing signs of **Obstructive Sleep Apnea (OSA)** or specific movement disorders, which this patient does not have.- The absence of snoring, apneas, or daytime sleepiness helps differentiate simple nocturnal panic from **primary sleep disorders**.*Nocturnal panic attacks are always secondary to nightmares and require trauma-focused therapy*- Unlike **nightmares** or **night terrors**, which occur during REM sleep or Stage 4 sleep respectively, nocturnal panic attacks occur without a dream trigger.- **Trauma-focused therapy** is indicated for PTSD-related nightmares, but the spontaneous nature of panic attacks requires standard **CBT for Panic Disorder**.
Question 19: A 36-year-old woman with moderate depression has been taking citalopram 20mg daily for 5 weeks. She reports some improvement in energy levels and sleep, but low mood and anhedonia persist. She asks whether she should increase the dose or try a different medication. What is the most appropriate response based on evidence-based guidelines?
- A. Switch to venlafaxine as she has had inadequate response to an SSRI
- B. Increase citalopram to 40mg daily as the current dose may be subtherapeutic
- C. Continue citalopram 20mg for at least another 2 weeks before making changes (Correct Answer)
- D. Add mirtazapine 15mg to augment the citalopram
- E. Switch to sertraline as it may be more effective for her symptoms
Explanation: ***Continue citalopram 20mg for at least another 2 weeks before making changes*** - Evidence-based guidelines (e.g., **NICE**) recommend an adequate trial of **6–8 weeks** at a therapeutic dose before determining a treatment is ineffective. - Since the patient is showing **partial improvement** (energy and sleep) at 5 weeks, maintaining the current dose is appropriate to allow the full therapeutic effect to manifest. *Switch to venlafaxine as she has had inadequate response to an SSRI* - Switching to an **SNRI** like venlafaxine is generally reserved for patients who have failed at least one full **6–8 week trial** of an SSRI. - It is premature to switch classes when the patient is currently experiencing a **positive trajectory** and has not reached the minimum trial duration. *Increase citalopram to 40mg daily as the current dose may be subtherapeutic* - **Citalopram 20mg** is a standard therapeutic dose; increasing it before the 8-week mark may unnecessarily increase the risk of **dose-dependent side effects** such as **QT prolongation**. - Dose escalation is typically considered only after an adequate time trial shows a **stall in progress** or insufficient response. *Add mirtazapine 15mg to augment the citalopram* - **Augmentation strategies** are secondary steps in treatment-resistant depression protocols, usually occurring after several failed monotherapy trials. - Introducing a second agent at this stage significantly increases the **pill burden** and risk of adverse effects without a proven need. *Switch to sertraline as it may be more effective for her symptoms* - Switching from one **SSRI** to another is a valid strategy for non-responders, but this patient is already demonstrating a **partial response**. - Changing medications now resets the **latency period** for clinical effect, potentially delaying the patient's recovery process.
Question 20: A 48-year-old woman with severe depression and prominent psychomotor retardation has been on optimal doses of fluoxetine for 8 weeks and subsequently venlafaxine for 10 weeks, with no significant improvement. Augmentation with lithium and then quetiapine has been tried without success. She has lost 8kg in weight and is drinking minimal fluids. Her psychiatrist recommends electroconvulsive therapy (ECT). What is the most likely clinical reason ECT is being considered at this stage?
- A. ECT is always indicated after two failed antidepressant trials
- B. The severe depression with life-threatening physical decline requires rapid intervention (Correct Answer)
- C. ECT is first-line treatment for depression with psychomotor retardation
- D. The patient has not responded to augmentation strategies so ECT is the only remaining option
- E. Psychomotor symptoms respond better to ECT than to pharmacotherapy
Explanation: ***The severe depression with life-threatening physical decline requires rapid intervention*** - **Electroconvulsive therapy (ECT)** is indicated as a first-line or urgent intervention when depression results in **life-threatening physical decline**, such as severe **dehydration** and significant **weight loss**. - ECT provides the **fastest onset of action** and highest response rates (70-90%) for patients residing in a critical state where pharmacotherapy would take too long to work. *ECT is always indicated after two failed antidepressant trials* - While treatment-resistant depression (TRD) is an indication, there is no rule that ECT is **"always"** indicated; it depends on the **severity**, clinical context, and patient preference. - Guidelines suggest considering it after multiple failures, but the immediate priority here is the **medical urgency**, not just the number of failed trials. *ECT is first-line treatment for depression with psychomotor retardation* - Pharmacotherapy remains the standard **first-line treatment** for most depressive presentations regardless of the presence of psychomotor retardation. - ECT is typically reserved for cases where there is **treatment resistance**, **psychotic features**, **catatonia**, or an immediate **risk to life**. *The patient has not responded to augmentation strategies so ECT is the only remaining option* - Other pharmacological options like **MAOIs**, alternative augmentation, or switching to different classes (e.g., tricyclics) remain, so ECT is not the **exclusive** remaining choice. - The decision for ECT is driven by the **clinical urgency** of her physical state rather than the exhaustion of every possible drug combination. *Psychomotor symptoms respond better to ECT than to pharmacotherapy* - While it is true that **psychomotor retardation** and **catatonic features** show high sensitivity to ECT, this pharmacological comparison is not the primary reason for its use here. - The recommendation is based on the need for a **rapid response** to prevent further physical deterioration from her **minimal fluid intake**.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free